A Multicenter, Open-label, Phase 2, Extension Trial to Study the Long-term Safety in Participants With PROS or Proteus Syndrome Who Are Currently Being Treated With Miransertib in Other Studies
Latest Information Update: 11 Nov 2022
At a glance
- Drugs Miransertib (Primary)
- Indications Growth disorders; Proteus syndrome
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 08 Nov 2022 Planned End Date changed from 15 Dec 2025 to 29 Sep 2026.
- 08 Nov 2022 Planned primary completion date changed from 15 Dec 2025 to 29 Sep 2026.
- 12 Oct 2022 Status changed from recruiting to active, no longer recruiting.